Plasmodium falciparum proteome (P. falciparum proteome)

The Plasmodium falciparum proteome encompasses the complete set of proteins expressed by the most lethal species of malaria parasite, totaling approximately 5,400 distinct gene products (UniProt, 2024). This extensive collection of proteins is responsible for the parasite's ability to infect human hosts, replicate within red blood cells, and evade the immune system through complex mechanisms like antigenic variation (NCBI, 2023). While the proteome itself is not a single therapeutic target, it contains numerous specific proteins that are the focus of drug development, including enzymes involved in folate synthesis and mitochondrial function (PubMed, 2022). Current antimalarial drugs, such as artemisinins and chloroquine, act by disrupting critical pathways or inducing widespread damage across multiple proteomic components (Nature, 2020). Understanding the proteome's dynamics is essential for identifying new drug targets and monitoring the genetic mutations that lead to widespread drug resistance (WHO, 2023). Furthermore, proteomic research aids in the discovery of diagnostic biomarkers and potential vaccine candidates to reduce the global burden of malaria (Science, 2021).

Other names

Malaria parasite proteomeP. falciparum proteinsPlasmodium falciparum total protein set

Antimalarial agents target the proteome through diverse mechanisms: quinolines inhibit heme detoxification; antifolates inhibit dihydropteroate synthase and dihydrofolate reductase; artemisinins undergo reductive activation to form free radicals that alkylate various parasite proteins; and atovaquone disrupts the mitochondrial electron transport chain (PubMed, 2023).